Table 6.
Effect on QOL (SF-36).
| Group | Day 0 | Day 180 | P value |
|---|---|---|---|
| Overall Quality of Life [Mean ± SD (CI)] | |||
| Treatment Group (n = 30) | 2206 ± 584.93 (1987.6–2424.4) | 2527 ± 611.69 (2298.6–2755.4)∗, @@@ | 0.042 0.0011 |
| Placebo Group (n = 28) | 2162.14 ± 436.75 (1992.8–2331.5) | 2050 ± 423.58 (1885.7–2214.3) | 0.33 |
| Physical function [Mean ± SD (CI)] | |||
| Treatment Group (n = 30) | 67.33 ± 22.70 (58.86–75.81) | 75.83 ± 21.41 (67.94–83.72) ∗∗∗ | 0.0003 0.07 |
| Placebo Group (n = 28) | 69.64 ± 19.15 (62.22–77.07) | 65.18 ± 23.63 (56.07–74.34)∗ | 0.03 |
| Role limitations due to physical health [Mean ± SD (CI)] | |||
| Treatment Group (n = 30) | 53.89 ± 39.86 (39.01–68.77) | 63.33 ± 38.13 (49.10–77.57) ∗ | 0.05 0.23 |
| Placebo Group (n = 28) | 53.57 ± 37.09 (39.19–67.96) | 51.79 ± 35.96 (37.84–65.73) | 0.57 |
| Role limitations due to emotional problems [Mean ± SD (CI)] | |||
| Treatment Group (n = 30) | 58.89 ± 40.76 (43.67–74.11) | 66.67 ± 38.16 (52.42–80.91) | 0.16 0.18 |
| Placebo Group (n = 28) | 50 ± 37.95 (35.28–64.72) | 53.57 ± 36.67 (39.35–67.79) | 0.38 |
| Energy [Mean ± SD (CI)] | |||
| Treatment Group (n = 30) | 61.22 ± 22.28 (52.90–69.54) | 66.67 ± 20.14 (59.15–74.19) ∗∗∗,@ | 0.009 0.02 |
| Placebo Group (n = 28) | 59.64 ± 15.57 (53.61–65.68) | 56.07 ± 15.60 (50.02–62.12)∗ | 0.05 |
| Emotional well-being [Mean ± SD (CI)] | |||
| Treatment Group (n = 30) | 61.07 ± 21.55 (53.02–69.11) | 69.60 ± 18.09 (62.85–76.36) ∗∗∗,@@@ | 0.0003 0.0003 |
| Placebo Group (n = 28) | 56.86 ± 17.77 (49.97–63.75) | 51.43 ± 17.48 (44.65–58.21)∗∗∗ | 0.001 |
| Social Functioning [Mean ± SD (CI)] | |||
| Treatment Group (n = 30) | 68.17 ± 20.08 (60.67–75.66) | 73.58 ± 23.16 (64.94–82.23) @@@ | 0.10 0.0006 |
| Placebo Group (n = 28) | 60.71 ± 16.91 (54.16–67.27) | 56.25 ± 16.84 (49.72–62.78) | 0.07 |
| Pain [Mean ± SD (CI)] | |||
| Treatment Group (n = 30) | 73.25 ± 24.12 (64.25–82.25) | 80.5 ± 19.98 (73.04–87.96) ∗∗,@@@ | 0.01 0.0001 |
| Placebo Group (n = 28) | 58.93 ± 19.38 (51.41–66.45) | 56.52 ± 17.56 (49.71–63.33) | 0.39 |
| General health [Mean ± SD (CI)] | |||
| Treatment Group (n = 30) | 53.33 ± 18.82 (46.31–60.36) | 64.5 ± 20.31 (56.92–72.09)∗∗∗,@ | 0.001 0.02 |
| Placebo Group (n = 28) | 56.07 ± 15.95 (49.89–62.26) | 52.86 ± 17.82 (45.95–59.77) | 0.18 |
Results are expressed as Mean ± SD (95% Confidence Interval).
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 as compared to Day 0 using paired Student's ‘t’ test in case of parametric data or Wilcoxon's matched pairs test in case of non-parametric data.
@p < 0.05, @@p < 0.01, @@@p < 0.001 as compared to Placebo Group using unpaired Student's ‘t’ test in case of parametric data or Mann–Whitney test in case of non-parametric data.